SCHEMBL21325344

SCHEMBL21325344

CC(C)(C)[C@@H]1CCCc2c1ccc(F)c2OCC1CC1

nearest known ligand 0.34

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 4/20 0.34
FEN1 P39748 4/20 0.34
RIPK1 Q13546 1/20 0.33
FFAR1 O14842 3/20 0.31
HTR2A P28223 2/20 0.31
HTR2C P28335 2/20 0.31
HTR2B P41595 2/20 0.31
CNR2 P34972 3/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21325048 1.00 ALOX5AP (0.34) ALOX5APFEN1RIPK1FFAR1HTR2A
SCHEMBL21325054 0.96 ALOX5AP (0.34) ALOX5APFEN1RIPK1FFAR1HTR2A
SCHEMBL21325053 0.92 RIPK1 (0.34) ALOX5APFEN1RIPK1FFAR1HTR2A
SCHEMBL21325347 0.92 RIPK1 (0.34) ALOX5APFEN1RIPK1FFAR1HTR2A
SCHEMBL21324914 0.85 FABP4 (0.37) ALOX5APFEN1RIPK1HTR2CHTR2B
SCHEMBL21533824 0.85 FABP4 (0.37) ALOX5APFEN1RIPK1HTR2CHTR2B
SCHEMBL20206761 0.83 FEN1 (0.36) ALOX5APFEN1FFAR1HTR2AHTR2C
SCHEMBL20376466 0.83 FEN1 (0.36) ALOX5APFEN1FFAR1HTR2AHTR2C
SCHEMBL22751137 0.81 FABP4 (0.39) RIPK1HTR2CHTR2BCNR2HCRTR1
SCHEMBL21533978 0.80 FEN1 (0.37) ALOX5APFEN1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 US disclosed
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 US disclosed
US-20200039966-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-06 US disclosed
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD ALOX5AP 3330/4885FEN1 52/4885RIPK1 3321/4885
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD ALOX5AP 2919/4885FEN1 108/4885RIPK1 3869/4885
US-20200039966-A1 URACIL CONTAINING COMPOUNDS UNG, DPYD, DUT ALOX5AP 2695/4885FEN1 21/4885RIPK1 3431/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT ALOX5AP 2695/4885FEN1 21/4885RIPK1 3431/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD ALOX5AP 3330/4885FEN1 52/4885RIPK1 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.